Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

Journal Browser

Role of Interleukins in Cutaneous Diseases and Novel Therapeutic Approaches

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 8980

Share This Special Issue

Special Issue Editor

Dr. Francesco Borgia

E-Mail Website
Guest Editor

Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98125 Messina, Italy
Interests: skin; basal cell carcinoma; squamous cell carcinoma; dermatology imaging; photodynamic therapy (PDT); phototherapy; skin cancer; biopsy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Interleukins are a large group of immunomodulatory proteins that elicit a wide variety of responses in cells and tissues. Interleukins initiate a response by binding to high-affinity receptors located on the surface of cells thus exerting various physiological activities. Interleukin production pathways, gene regulation mechanisms, receptor systems, and signal transduction have been investigated. In the last decade, interleukins have been shown to play a central role in the pathogenesis of various skin diseases, including atopic dermatitis, psoriasis, chronic spontaneous urticaria, systemic lupus erythematosus, systemic sclerosis and cancer. Moreover, it is now becoming clear that interleukins are involved in biological responses before the onset of disease, not only in intercellular networks but also in interorgan ones. Moving through this complex scenario, some of these molecules have been already studied as novel biomarkers for specific targeted therapies. New studies investigating the role of these molecules as part of a complex and wide biological net are needed to better understand their role in biological systems.

This Special Issue proposal focuses on the role of interleukins in the pathogenesis of skin diseases and their possible role as novel therapeutic targets. Potential topics include, but are not limited to:

Research roles of interleukins in the pathogenesis of conditions of high social interest
Possible therapeutic role of interleukins and biological drugs directed towards them
Possible cross links between different conditions that present similar cytokine profile
Possible role of physiological and pathological variations of interleukin sequence
Role of systemic conditions in the expression of specific cytokines
Role of external and internal environment in cytokine production and disease course
Define signal cascade to allow blockade of interleukins at various levels depending on patient general conditions

Dr. Francesco Borgia
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

interleukin
skin diseases
Th-1
Th2
T-cells
immune system
immunological disease
biological drugs
psoriasis
atopic dermatitis
systemic lupus erythematosus

Published Papers (3 papers)

Download All Papers

Research

Jump to: Review

14 pages, 2862 KiB

Open AccessArticle

Therapeutic Effectiveness of Interferon-α2b against COVID-19 with Community-Acquired Pneumonia: The Ukrainian Experience

by Aleksandr Kamyshnyi, Halyna Koval, Olha Kobevko, Mykhailo Buchynskyi, Valentyn Oksenych, Denis Kainov, Katerina Lyubomirskaya, Iryna Kamyshna, Geert Potters and Olena Moshynets

Int. J. Mol. Sci. 2023, 24(8), 6887; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms24086887 - 07 Apr 2023

Cited by 6 | Viewed by 1866

Abstract

Despite several targeted antiviral drugs against SARS-CoV-2 currently being available, the application of type I interferons (IFNs) still deserves attention as an alternative antiviral strategy. This study aimed to assess the therapeutic effectiveness of IFN-α in hospitalized patients with COVID-19-associated pneumonia. The prospective cohort study included 130 adult patients with coronavirus disease (COVID-19). A dose of 80,000 IU of IFN-α2b was administered daily intranasally for 10 days. Adding IFN-α2b to standard therapy reduces the length of the hospital stay by 3 days (p < 0.001). The level of CT-diagnosed lung injuries was reduced from 35% to 15% (p = 0.011) and CT injuries decreased from 50% to 15% (p = 0.017) by discharge. In the group of patients receiving IFN-α2b, the SpO2 index before and after treatment increased from 94 (92–96, Q₁–Q₃) to 96 (96–98, Q₁–Q₃) (p < 0.001), while the percentage of patients with normal saturation increased (from 33.9% to 74.6%, p < 0.05), but the level of SpO2 decreased in the low (from 52.5% to 16.9%) and very low (from 13.6% to 8.5%) categories. The addition of IFN-α2b to standard therapy has a positive effect on the course of severe COVID-19. Full article

(This article belongs to the Special Issue Role of Interleukins in Cutaneous Diseases and Novel Therapeutic Approaches)

► Show Figures

Figure 1

10 pages, 1397 KiB

Open AccessCommunication

Dermatophagoides farinae Extract Induces Interleukin 33-Mediated Atopic Skin Inflammation via Activation of RIP1

by Meiling Jin, Jin Seon Bang, Dae-Lyong Ha, Jun Young Kim, Kyung Duck Park, Weon Ju Lee, Seok-Jong Lee, Jin Kyeong Choi, Young-Ae Choi, Yong Hyun Jang and Sang-Hyun Kim

Int. J. Mol. Sci. 2023, 24(6), 5228; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms24065228 - 09 Mar 2023

Viewed by 1437

Abstract

Receptor-interacting protein kinase (RIP) family 1 signaling has complex effects on inflammatory processes and cell death, but little is known concerning allergic skin diseases. We examined the role of RIP1 in Dermatophagoides farinae extract (DFE)-induced atopic dermatitis (AD)-like skin inflammation. RIP1 phosphorylation was increased in HKCs treated with DFE. Nectostatin-1, a selective and potent allosteric inhibitor of RIP1, inhibited AD-like skin inflammation and the expression of histamine, total IgE, DFE-specific IgE, IL-4, IL-5, and IL-13 in an AD-like mouse model. The expression of RIP1 was increased in ear skin tissue from a DFE-induced mouse model with AD-like skin lesions and in the lesional skin of AD patients with high house dust mite sensitization. The expression of IL-33 was down-regulated after RIP1 inhibition, and the levels of IL-33 were increased by over-expression of RIP1 in keratinocytes stimulated with DFE. Nectostatin-1 reduced IL-33 expression in vitro and in the DFE-induced mouse model. These results suggest that RIP1 can be one of the mediators that regulate IL-33-mediated atopic skin inflammation by house dust mites. Full article

(This article belongs to the Special Issue Role of Interleukins in Cutaneous Diseases and Novel Therapeutic Approaches)

► Show Figures

Figure 1

Review

Jump to: Research

20 pages, 2914 KiB

Open AccessReview

IL-31: State of the Art for an Inflammation-Oriented Interleukin

by Francesco Borgia, Paolo Custurone, Federica Li Pomi, Raffaele Cordiano, Clara Alessandrello and Sebastiano Gangemi

Int. J. Mol. Sci. 2022, 23(12), 6507; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23126507 - 10 Jun 2022

Cited by 19 | Viewed by 5212

Abstract

Interleukin 31 belongs to the IL-6 superfamily, and it is an itch mediator already studied in several diseases, comprising atopic dermatitis, allergic pathologies, and onco-hematological conditions. This research aims to assess the role of this cytokine in the pathogenesis of these conditions and its potential therapeutic role. The research has been conducted on articles, excluding reviews and meta-analysis, both on animals and humans. The results showed that IL-31 plays a crucial role in the pathogenesis of systemic skin manifestations, prognosis, and itch severity. Traditional therapies target this interleukin indirectly, but monoclonal antibodies (Mab) directed against it have shown efficacy and safety profiles comparable with biological drugs that are already available. Future perspectives could include the development of new antibodies against IL-31 both for humans and animals, thus adding a new approach to the therapy, which often has proven to be prolonged and specific for each patient. Full article

(This article belongs to the Special Issue Role of Interleukins in Cutaneous Diseases and Novel Therapeutic Approaches)

► Show Figures